Navigation Links
Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances
Date:7/13/2009

SAN MARINO, Calif.,July 13 /PRNewswire-FirstCall/ -- Viral Genetics (Pink Sheets: VRAL), a biotechnology company that develops drug compounds for HIV/AIDS, autoimmune diseases, and cancer, has retired the majority of its $3.5 million of convertible debt. The company also retired other debt and recently issued new shares.

The convertible debt originated with a March 2006 financing through the issuance of shares. This transaction originally was disclosed March 29, 2006, in a report filed on Form 8-K, with amendments filed March 2, 2007, and August 18, 2008. The company has paid all but approximately $110,000 of the principal on the $2.9 million of 10% senior secured amortizing convertible notes issued in that financing.

At that time, eleven institutional purchasers also acquired approximately $598,000 of unsecured convertible notes held by other third parties. These notes are now substantially discharged through conversion to stock, and have approximately $8,000 of remaining amounts owed under them.

All payments on both series of notes were made in shares of common stock of the company. Since Viral Genetics' February 17, 2009 Form 8-K report, the company has issued 33,751,347 common shares for the repayment of these notes.

Since March 2009, Viral Genetics has issued shares in exchange for accounts payable, advances, and private placements valued at approximately $700,000. The private placements included 33,142,800 shares and 24,200,000 warrants. Each warrant entitles the holder to purchase common stock for $0.03 per share, expiring May and June 2011. Of the shares, 19,452,800 were issued under Regulation 504 financing.

In May 2009, the company issued 5,788,945 shares and 11,577,890 warrants for advances of cash previously received in 2008 and 2009. Each of these warrants entitles the holder to acquire one share of common stock a
'/>"/>

SOURCE Viral Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Viral Genetics Information Now Available Through OTCIQ.com and Pink Sheets Website
2. New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance
3. BIO Visitors Bring Viral Preparedness to Atlanta
4. Antiviral Drugmaker Shares Soar as Swine Flu Spreads; Beacon Equity Issues Stock Alerts on: HEB, GNBT, BCRX, DVAX, NVAX, SVA
5. INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
6. Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray
7. Advanced Viral Announces Phase IIb Wound Healing Trial for AVR123
8. Researchers decode viral process that prepares cells for HIV infection
9. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
10. World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic
11. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... the health of your heart, researchers have discovered. , ... standard TENS machine like those designed to relieve labour ... small raised flap at the front of the ear ... stimulation changed the influence of the nervous system on ... drive failing hearts too hard. , Professor Jim Deuchars, ...
(Date:8/20/2014)... 2014 GraphDB™ 6.0 ... improvements to the enterprise replication cluster, faster loading ... SOLR and Elasticsearch. This release happens to coincide ... triplestore – GraphDB™ was formerly known as OWLIM. ... only mature enterprise resilient RDF triplestore will also ...
(Date:8/19/2014)... Columbia, Md. (PRWEB) August 19, 2014 ... integrated liquid chromatography systems, Prominence-i and Nexera-i, adding ... UHPLC systems. Combining excellent functionality, an intuitive operating ... performance and a more efficient workflow for conventional ... systems feature innovative, intuitive and intelligent design so ...
(Date:8/19/2014)... A Geisinger researcher on a personal crusade ... for Disease Control and Prevention (CDC) award recognizing his ... Joseph Boscarino , Ph.D. MPH, senior ... of researchers nominated for the Centers for Disease Control ... Data Methods and Study Design. "Hepatitis C ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... SAN DIEGO and ST. LOUIS, June 27, 2011 ... industrial biotechnology company focused on the development and commercialization ... manufacturer of animal and human nutrition and health products, ... commercialize a suite of new enzyme products from Verenium,s ...
... of our nation,s long-term clean-energy future, but the technology ... Japan,s recent Fukushima disaster. Indeed, many nations have called ... are operating safely. In the United States, ... percent of the electricity from emission-free sources, including renewable ...
... France, June 24, 2011 Mediabrands, IPG Media ... Lions International Advertising Festival, the results of the ... MIT, Affectiva is able to record and measure ... correlating to an individual,s facial features are established ...
Cached Biology Technology:Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 2Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 3Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 4Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 5Berkeley scientists pioneer nanoscale nuclear materials testing capability 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3
(Date:8/20/2014)... at Huntsman Cancer Institute (HCI) at the University of ... gene that encodes BCR-ABL, the unregulated enzyme driving the ... American Cancer Society, nearly 6,000 new cases of CML ... use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL and ... cure CML but control it in a way that ...
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... sweet and salty aroma of sunscreen and seawater signals ... now reporting that the idyllic beach vacation comes with ... skin and into the sea, they can become toxic ... the main course for many other marine animals. Their ... & Technology . , Antonio Tovar-Sanchez and David Snchez-Quiles ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... is available in German . , ... has developed a model, which identifies potential habitats and corridors ... Rheinland-Pfalz as an example, it was demonstrated that almost half ... enabling a maximum population of 1600 females. The model can ...
... is a link between alcohol consumption and increased risk of ... 5,870 young adult women. The study, published in ... found that the risk increased 3% for every additional alcoholic ... observe any increase in risk of seasonal allergic rhinitis according ...
... Achieves record biometric revenues and profitability, WALL, ... Board: BKYI), a leader in wireless public safety ... profitability and strong revenue growth for its second ... continuing operations for the quarter ended June 30,2008 ...
Cached Biology News:Let the cat keep chasing the mouse 2Let the cat keep chasing the mouse 3Let the cat keep chasing the mouse 4Alcohol is associated with risk of perennial allergic rhinitis 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 3BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 4BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 5
Mouse polyclonal antibody raised against a partial recombinant LASS3. NCBI Entrez Gene ID = 204219...
... is a sample preparation kit for reduction ... of detergents, phenolic compounds, salts, and most ... samples. The kit procedure involves a TCA-like ... or cells, plant leaves, E. coli, and ...
... Myosin II Heavy Chain Isoform B ... + 0.03% Thimerosal) This antibody was ... to the C-terminus of nonmuscle myosin ... antibody is effective in immunoblotting and ...
MAb to Catenin beta, N-terminal (exon 2) Catenin, beta, N-terminal (exon 2)...
Biology Products: